INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAA6. A total of 45 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $1,631,000 | -64.2% | 2,000,000 | -55.6% | 0.00% | -50.0% |
Q4 2019 | $4,562,000 | -24.3% | 4,500,000 | -35.7% | 0.00% | -33.3% |
Q3 2019 | $6,029,000 | -3.3% | 7,000,000 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $6,237,000 | -10.2% | 7,000,000 | 0.0% | 0.00% | 0.0% |
Q1 2019 | $6,947,000 | +14.8% | 7,000,000 | +16.7% | 0.00% | 0.0% |
Q3 2018 | $6,050,000 | -55.5% | 6,000,000 | -61.3% | 0.00% | -57.1% |
Q2 2018 | $13,596,000 | +14.4% | 15,500,000 | +4.7% | 0.01% | +16.7% |
Q1 2018 | $11,881,000 | -26.8% | 14,800,000 | -27.1% | 0.01% | -40.0% |
Q4 2017 | $16,226,000 | +17.2% | 20,300,000 | +14.0% | 0.01% | -9.1% |
Q3 2017 | $13,845,000 | -70.5% | 17,800,000 | -63.0% | 0.01% | -72.5% |
Q2 2017 | $46,963,000 | +16.7% | 48,100,000 | +11.6% | 0.04% | +8.1% |
Q1 2017 | $40,244,000 | -8.8% | 43,100,000 | -12.2% | 0.04% | -17.8% |
Q4 2016 | $44,104,000 | -29.6% | 49,100,000 | -12.3% | 0.04% | -28.6% |
Q3 2016 | $62,688,000 | – | 56,000,000 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Silver Point Capital L.P. | 57,420,000 | $44,527,000 | 5.17% |
Birch Grove Capital LP | 10,003,000 | $7,934,000 | 4.14% |
PenderFund Capital Management Ltd. | 9,605,000 | $9,491,000 | 2.41% |
Context Capital Management, LLC | 9,887,000 | $7,671,000 | 1.05% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 57,791,000 | $45,738,000 | 0.90% |
DeepCurrents Investment Group LLC | 35,892,000 | $27,953,000 | 0.74% |
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 22,977,000 | $18,267,000 | 0.70% |
WHITEBOX ADVISORS LLC | 23,150,000 | $17,847,000 | 0.56% |
ADVENT CAPITAL MANAGEMENT /DE/ | 27,397,000 | $21,720,000 | 0.46% |
OAKTREE CAPITAL MANAGEMENT LP | 19,435,000 | $15,079,000 | 0.26% |